Published in Antimicrob Agents Chemother on February 01, 2002
Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother (2006) 1.89
Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother (2003) 1.47
Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother (2002) 1.46
Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. Antimicrob Agents Chemother (2007) 1.01
Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother (2010) 1.01
Internalization of Staphylococcus aureus in lymphocytes induces oxidative stress and DNA fragmentation: possible ameliorative role of nanoconjugated vancomycin. Oxid Med Cell Longev (2011) 0.87
Contribution of Catalase and Superoxide Dismutase to the Intracellular Survival of Clinical Isolates of Staphylococcus aureus in Murine Macrophages. Indian J Microbiol (2011) 0.83
Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model. Antimicrob Agents Chemother (2009) 0.83
Influence of the protein kinase C activator phorbol myristate acetate on the intracellular activity of antibiotics against hemin- and menadione-auxotrophic small-colony variant mutants of Staphylococcus aureus and their wild-type parental strain in human THP-1 cells. Antimicrob Agents Chemother (2012) 0.78
Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer (1980) 10.11
Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J Antimicrob Chemother (1986) 2.27
Uptake of ciprofloxacin by macrophages. J Clin Pathol (1985) 2.01
Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity. Antimicrob Agents Chemother (1986) 1.97
Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother (1994) 1.60
Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob Agents Chemother (1990) 1.51
Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother (1990) 1.45
Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob Agents Chemother (1992) 1.37
Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (1996) 1.30
Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother (1999) 1.27
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother (2001) 1.20
Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells. Antimicrob Agents Chemother (1997) 1.15
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs (2000) 1.14
Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1994) 1.07
Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimicrob Agents Chemother (1997) 1.00
Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob Agents Chemother (1996) 0.99
Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother (1999) 0.98
Intracellular pharmacokinetics and localization of antibiotics as predictors of their efficacy against intraphagocytic infections. Scand J Infect Dis Suppl (1990) 0.96
Uptake and intracellular activity of fleroxacin in phagocytic cells. Chemotherapy (1996) 0.90
Cellular transport of drugs. Clin Infect Dis (1994) 0.90
Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother (1999) 0.90
Antibiotics and neutrophil function--potential immunomodulating activities. J Antimicrob Chemother (1993) 0.90
Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G. J Antimicrob Chemother (1999) 0.88
Comparative uptake of sparfloxacin and ciprofloxacin into human THP 1 monocytic cells. Arzneimittelforschung (1996) 0.83
Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (1998) 0.83
In vitro extracellular and intracellular activity of two newer and two earlier fluoroquinolones against Listeria monocytogenes. Eur J Clin Microbiol Infect Dis (1997) 0.83
Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1996) 0.82
Intracellular microorganisms: a particular problem for chemotherapy. Introduction. Infection (1991) 0.82
Activities of antimicrobial agents against intracellular pneumococci. Antimicrob Agents Chemother (2000) 0.81
In-vitro tests of the functions of phagocytic cells and their interaction with antimicrobial agents: a critical view. J Antimicrob Chemother (1990) 0.80
An in vitro investigation of the intraphagocytic bioactivity of difloxacin, ciprofloxacin, pefloxacin and fleroxacin. Chemotherapy (1989) 0.77
Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother (2001) 0.77
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Molecular characterization of a novel class 1 integron containing bla(GES-1) and a fused product of aac3-Ib/aac6'-Ib' gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2002) 2.65
Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med (2005) 2.61
Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med (2003) 2.40
Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med (2008) 1.75
Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med (2007) 1.64
Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal (2009) 1.63
Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS (2004) 1.35
Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother (2003) 1.33
Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med (2004) 1.23
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther (2006) 1.19
Type II topoisomerase quinolone resistance-determining regions of Aeromonas caviae, A. hydrophila, and A. sobria complexes and mutations associated with quinolone resistance. Antimicrob Agents Chemother (2002) 1.11
Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS (2002) 1.11
Decreased susceptibility to cefepime in a clinical strain of Escherichia coli related to plasmid- and integron-encoded OXA-30 beta-lactamase. Antimicrob Agents Chemother (2003) 1.08
Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med (2006) 1.06
Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother (2012) 1.06
Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). J Antimicrob Chemother (2008) 1.05
Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. Antimicrob Agents Chemother (2008) 1.02
Protonation equilibrium and lipophilicity of moxifloxacin. J Pharm Biomed Anal (2005) 1.02
SHV-49, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother (2004) 1.01
CTX-M-producing Escherichia coli in a maternity ward: a likely community importation and evidence of mother-to-neonate transmission. J Antimicrob Chemother (2010) 0.97
Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med (2004) 0.97
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother (2009) 0.96
Prolonged outbreak of infection due to TEM-21-producing strains of Pseudomonas aeruginosa and enterobacteria in a nursing home. J Clin Microbiol (2005) 0.95
A new in vitro strand transfer assay for monitoring bacterial class 1 integron recombinase IntI1 activity. PLoS One (2007) 0.94
Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting. J Clin Microbiol (2005) 0.94
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrob Agents Chemother (2007) 0.94
Clinical strain of Pseudomonas aeruginosa carrying a bla(TEM-21) gene located on a chromosomal interrupted TnA type transposon. Antimicrob Agents Chemother (2002) 0.94
NDM-1-producing Klebsiella pneumoniae resistant to colistin in a French community patient without history of foreign travel. Antimicrob Agents Chemother (2012) 0.93
Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem (2011) 0.93
Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.93
TbtABM, a multidrug efflux pump associated with tributyltin resistance in Pseudomonas stutzeri. FEMS Microbiol Lett (2004) 0.92
High genetic stability of integrons in clinical isolates of Shigella spp. of worldwide origin. Antimicrob Agents Chemother (2007) 0.92
Dipeptidyl peptidase 8/9-like activity in human leukocytes. J Leukoc Biol (2007) 0.91
Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother (2004) 0.90
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther (2008) 0.89
Rapid identification of Listeria species by using restriction fragment length polymorphism of PCR-amplified 23S rRNA gene fragments. Appl Environ Microbiol (2003) 0.89
Occurrence of Listeria spp. in effluents of French urban wastewater treatment plants. Appl Environ Microbiol (2005) 0.89
Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Comb Chem High Throughput Screen (2006) 0.88
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance. Antimicrob Agents Chemother (2008) 0.88
Extended-spectrum-beta-lactamase-producing Enterobacteriaceae strains in various types of private health care centers. Antimicrob Agents Chemother (2007) 0.86
Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. Antimicrob Agents Chemother (2006) 0.86
Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med (2005) 0.86
In vitro recombination catalyzed by bacterial class 1 integron integrase IntI1 involves cooperative binding and specific oligomeric intermediates. PLoS One (2009) 0.86
Evaluation of the Osiris expert system for identification of beta-lactam phenotypes in isolates of Pseudomonas aeruginosa. J Clin Microbiol (2003) 0.85
Carbapenems. J Chemother (2013) 0.85
Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors. Bioorg Med Chem Lett (2008) 0.83
Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus. Expert Opin Pharmacother (2010) 0.82
Drug selection in French university hospitals: analysis of formularies for nine competitive pharmacological classes. Br J Clin Pharmacol (2011) 0.82
Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype. Antimicrob Agents Chemother (2010) 0.82
Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. Bioorg Med Chem Lett (2008) 0.82
Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus. J Antimicrob Chemother (2007) 0.81
Cross-infection due to imipenem-resistant Bacteroides fragilis associated with a totally implantable venous port. J Clin Microbiol (2002) 0.81
Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. J Acquir Immune Defic Syndr (2009) 0.80
Synthesis of new 4-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]quinoxaline and 5-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]thieno[3,2-e]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors. J Enzyme Inhib Med Chem (2007) 0.80
Severe community-acquired Enterobacter pneumonia: a plea for greater awareness of the concept of health-care-associated pneumonia. BMC Infect Dis (2011) 0.79
Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.79
Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes. J Antimicrob Chemother (2008) 0.79
Duplication of the chromosomal blaSHV-11 gene in a clinical hypermutable strain of Klebsiella pneumoniae. Microbiology (2010) 0.79
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus. Antimicrob Agents Chemother (2006) 0.79
Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. Arthritis Res Ther (2010) 0.79
TEM-80, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Enterobacter cloacae. Antimicrob Agents Chemother (2002) 0.78
Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study). J Antimicrob Chemother (2006) 0.78
Reverse aggregate nucleation induced by acids in liquid-liquid extraction processes. Phys Chem Chem Phys (2014) 0.78
Determination of free ertapenem in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.77
Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model. J Antimicrob Chemother (2006) 0.77
Determination of linezolid in growth media by high-performance liquid chromatography with on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.76
Quantitative analysis of erythropoietin in human plasma by tandem mass spectrometry. Anal Bioanal Chem (2011) 0.76
TEM-21 extended-spectrum beta-lactamase in a clinical isolate of Alcaligenes faecalis from a nursing home. J Antimicrob Chemother (2005) 0.76
Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storage. Am J Health Syst Pharm (2013) 0.75